FDA Commissioner Marty Makary Resigns After Trump Pressure
This story raises questions about governance, accountability, and American values.
The coverage treats Marty Makary’s resignation as proof that any pushback from Trump is automatically illegitimate. That framing assumes the FDA is healthiest when it is insulated from elected leadership, even when the public has lost confidence in its judgment and speed. Conservatives see a different problem: **unaccountable bureaucracy**.
New Republican Times Editorial Board
By Andria Park Huynh HealthDay ReporterWEDNESDAY, May 13, 2026 (HealthDay News) — After months of pressure from the Trump administration, U.S. Food
Original source:
Read at UsnewsHow We See It
New Republican Times Editorial Board
The coverage treats Marty Makary’s resignation as proof that any pushback from Trump is automatically illegitimate. That framing assumes the FDA is healthiest when it is insulated from elected leadership, even when the public has lost confidence in its judgment and speed.
Conservatives see a different problem: unaccountable bureaucracy. The FDA wields enormous power over innovation, prices, and access, yet too often hides behind process and press releases. Democratic oversight is not “pressure” when it demands timelines, transparency, and clear standards.
This is also about public trust and institutional stability. If decisions look like they serve insiders, confidence collapses. And in a world of supply shocks and biotech competition, national security includes a regulator that can move fast without cutting corners.
The principle at stake is simple: rule of law with accountability, not permanent autonomy for permanent Washington.
Commentary written with AI assistance by the New Republican Times Editorial Board.